Tyrus Capital S.A.M. purchased a new stake in Spectranetics Corp (NASDAQ:SPNC) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 156,000 shares of the medical equipment provider’s stock, valued at approximately $5,990,000. Spectranetics Corp makes up about 0.5% of Tyrus Capital S.A.M.’s investment portfolio, making the stock its 16th largest holding. Tyrus Capital S.A.M. owned approximately 0.36% of Spectranetics Corp at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rhumbline Advisers increased its holdings in Spectranetics Corp by 0.6% in the 2nd quarter. Rhumbline Advisers now owns 54,223 shares of the medical equipment provider’s stock valued at $2,082,000 after purchasing an additional 303 shares in the last quarter. Macquarie Group Ltd. increased its holdings in Spectranetics Corp by 0.8% in the 2nd quarter. Macquarie Group Ltd. now owns 71,029 shares of the medical equipment provider’s stock valued at $2,728,000 after purchasing an additional 540 shares in the last quarter. PEAK6 Investments L.P. increased its holdings in Spectranetics Corp by 7.6% in the 1st quarter. PEAK6 Investments L.P. now owns 11,526 shares of the medical equipment provider’s stock valued at $336,000 after purchasing an additional 816 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in Spectranetics Corp by 0.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 145,469 shares of the medical equipment provider’s stock valued at $5,586,000 after purchasing an additional 826 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in Spectranetics Corp by 0.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 171,443 shares of the medical equipment provider’s stock valued at $4,994,000 after purchasing an additional 889 shares in the last quarter. Hedge funds and other institutional investors own 91.95% of the company’s stock.

Shares of Spectranetics Corp (SPNC) remained flat at $38.45 during mid-day trading on Friday. 1,728,937 shares of the stock traded hands. Spectranetics Corp has a 12-month low of $19.80 and a 12-month high of $38.55. The company has a 50 day moving average price of $37.28 and a 200-day moving average price of $30.10.

Spectranetics Corp (NASDAQ:SPNC) last posted its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.29). Spectranetics Corp had a negative return on equity of 194.18% and a negative net margin of 32.93%. The company had revenue of $74.71 million for the quarter, compared to the consensus estimate of $73.82 million. During the same quarter in the previous year, the firm posted ($0.35) EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities research analysts anticipate that Spectranetics Corp will post ($1.16) EPS for the current year.

SPNC has been the subject of several recent analyst reports. Royal Bank Of Canada restated a “hold” rating and set a $27.00 target price on shares of Spectranetics Corp in a research note on Monday, July 24th. BidaskClub downgraded Spectranetics Corp from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Raymond James Financial, Inc. restated a “market perform” rating and set a $28.00 target price on shares of Spectranetics Corp in a research note on Tuesday, July 25th. Needham & Company LLC restated a “buy” rating and set a $38.50 target price on shares of Spectranetics Corp in a research note on Wednesday, June 28th. Finally, Northland Securities restated a “market perform” rating and set a $38.50 target price (up from $32.00) on shares of Spectranetics Corp in a research note on Wednesday, June 28th. Ten analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Spectranetics Corp currently has an average rating of “Hold” and an average target price of $35.36.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/tyrus-capital-s-a-m-purchases-new-holdings-in-spectranetics-corp-spnc.html.

About Spectranetics Corp

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Institutional Ownership by Quarter for Spectranetics Corp (NASDAQ:SPNC)

Receive News & Stock Ratings for Spectranetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics Corp and related stocks with our FREE daily email newsletter.